EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma

Peinan Zhao iD, Christopher Chew iD, Pacman Szeto iD, William Berry iD, Louise Photiou iD, Nicholas C Wong iD, Andrew Dinan iD, Catriona A McLean iD, Vikki M Marshall iD, Jen Cheung iD, Nikki R Adler iD, Farhad Goodarzy iD und 4 weitere

British Journal of Dermatology · 2026

DOI: 10.1093/bjd/ljaf507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Peinan Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, DNA Copy Number Variations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galli Medical Trust, National Health and Medical Research Council (NHMRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary dermal melanoma (PDM) is a subtype of melanoma with histological features indiscernible from nonepidermal metastatic cutaneous melanoma deposits, although patients with PDMs have more favourable outcomes than patients with dermal metastases. Despite the histological similarity, it is not known whether the mutational landscapes of PDMs and dermal metastases are also similar, or whether distinct mutational patterns might exist in PDMs.

Objectives

To identify genomic features that distinguish PDMs from nonepidermal cutaneous melanoma metastases, thereby enhancing the accuracy of clinical diagnosis and prognostication.

Methods

Twenty PDMs and 23 nonepidermal cutaneous metastases were sequenced using the TSO500 panel. Genomic features distinguishing PDMs and metastases were identified using the regularized random forest model and feature engineering. Predictive biomarkers of patient event-free survival were identified using Lasso–Cox regression.

Results

PDMs and nonepidermal cutaneous metastases harboured point mutations characteristic of melanomas of epidermal origin. Compared with PDMs, metastases exhibited distinct copy number variations (CNVs) that led to gains of oncogenes and losses of tumour suppressor genes. Extreme focal amplifications were uniquely identified in cases of nonepidermal cutaneous metastases but were absent in PDMs. Large-scale CNVs and focal amplifications were identified as discriminative biomarkers between PDMs and metastases. A clinical diagnosis of PDM and an absence of BRAF CNVs collectively were associated with a reduced risk of death or disease progression after surgery vs. a clinical diagnosis of metastasis or of PDM with BRAF CNVs.

Conclusion

We found that CNVs were the strongest discriminative features between PDMs and nonepidermal cutaneous metastases, with large-scale and focal CNVs abundant in metastases but not in PDMs. Notably, integrating BRAF copy number analysis with standard clinical criteria for diagnosing PDMs improved risk stratification after surgery. These data highlight the ability of panel-based genomic sequencing that enables the detection of CNVs to inform the clinical management of melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsDNA Copy Number VariationsHumansPrognosisMaleFemaleMiddle AgedAgedBiomarkers, TumorAdultPoint MutationDiagnosis, DifferentialAged, 80 and overProto-Oncogene Proteins B-rafCutaneous Malignant Melanoma

Substanzen

Biomarkers, TumorProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Cancer Medicine, Monash University, Melbourne, VIC, Australia.
  • Victorian Melanoma Service, Alfred Hospital, Melbourne, VIC, Australia.
  • Monash Bioinformatics Platform, Monash University, Melbourne, VIC, Australia.
  • Department of Anatomical Pathology, Alfred Hospital, Melbourne, VIC, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.

ORCID-Profile: Peinan Zhao, Christopher Chew, Pacman Szeto, William Berry, Louise Photiou, Nicholas C Wong, Andrew Dinan, Catriona A McLean, Vikki M Marshall, Jen Cheung, Nikki R Adler, Farhad Goodarzy, Miles C Andrews, Victoria J Mar, Anthony T Papenfuss, Mark Shackleton

Förderung

  • Galli Medical Trust
  • National Health and Medical Research Council (NHMRC)

Zitieren

APA

Zhao, P., Chew, C., Szeto, P., Berry, W., Photiou, L., Wong, N. C., Dinan, A., McLean, C. A., Marshall, V. M., Cheung, J., Adler, N. R., Goodarzy, F., Andrews, M. C., Mar, V. J., Papenfuss, A. T., & Shackleton, M. (2026). Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf507

Vancouver

Zhao P, Chew C, Szeto P, Berry W, Photiou L, Wong NC, et al. Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljaf507

BibTeX
@article{Zhao2026,
  author = {Zhao, Peinan and Chew, Christopher and Szeto, Pacman and Berry, William and Photiou, Louise and Wong, Nicholas C and Dinan, Andrew and McLean, Catriona A and Marshall, Vikki M and Cheung, Jen and Adler, Nikki R and Goodarzy, Farhad and Andrews, Miles C and Mar, Victoria J and Papenfuss, Anthony T and Shackleton, Mark},
  title = {Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljaf507}
}
Kostenlos starten →